P1239 HIGH SVR24 RATES WITH MERICITABINE (MCB), TELAPREVIR (TVR) PLUS PEGIFN ALFA-2a/RIBAVIRIN (P/R) IN HCV G1-INFECTED PRIOR NULL RESPONDERS: RESULTS FROM DYNAMO 2 von Sherman, K.E, Forns, X, Scalori, A, Zhao, S, Voulgari, A, Thommes, J

Volltext

P1238 SVR24 RATE OF 60% IN HCV G1-INFECTED PRIOR NULL RESPONDERS TREATED WITH MERICITABINE (MCB), BOCEPREVIR (BOC) PLUS PEGIFN ALFA-2a/RIBAVIRIN (P/R): RESULTS FROM DYNAMO 1 von Wedemeyer, H, Hézode, C, Lee, S.S, Scalori, A, Zhao, S, Voulgari, A, Thommes, J

Volltext

773 RS12979860 CC GENOTYPE IS ASSOCIATED WITH BASELINE HIGH NUMBERS OF CD56BRIGHT NK-CELLS, LOW NUMBERS OF CD3-CD56-CD16– CELLS, LOW IL-10 HCV-SPECIFIC PRODUCTION IN CH-C THERAPY R... von Carey, I, Bruce, M, Joshi, D, Mendes, A, Scalori, A, Agarwal, K, Vergani, D

Volltext

P57 The IL28B gene SNP rs12979860 CC haplotype, predictor of response to treatment in chronic HCV infection, is associated to high numbers of CD56bright NK cells, low numbers of CD... von Carey, I, Bruce, M, Mendes, A, Scalori, A, Joshi, D, Agarwal, K, Mieli-Vergani, G, Vergani, D

Volltext

1145 HIGH NUMBERS OF CD56BRIGHT , CD56DIM /NKG2D+ AND LOW NUMBERS OF CD3 CD56 CD16+ NK-CELLS ARE ASSOCIATED WITH LOW HCV-SPECIFIC IL-10 PRODUCTION AND PREDICT TREATMENT-RESPONSE IN... von Carey, I, Mendes, A, Scalori, A, Joshi, D, Agarwal, K, Mieli-Vergani, G, Vergani, D

Volltext

Oral contraceptives and the risk of focal nodular hyperplasia of the liver: A case-control study von Scalori, Astrid, Tavani, Alessandra, Gallus, Silvano, La Vecchia, Carlo, Colombo, Massimo

Volltext

P67 Switch to other nucleos(t)ide analogues therapy in chronic hepatitis B cohort on long-term de-novo combination therapy with lamivudine plus adefovir: efficacy and safety von Carey, I, Mendes, A, Joshi, D, Bruce, M, Knighton, S, Scalori, A, Hughes, S, Al-Freah, M, Suddle, A, Harrison, P M, Agarwal, K

Volltext

707 LONG-TERM DE-NOVO LAMIVUDINE + ADEFOVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B IS EFFICIENT, BUT HAS NEGATIVE IMPACT ON RENAL/BONE SAFETY IN COMPARISON TO ENTECAVIR MONOTHE... von Carey, I, Mendes, A, Joshi, D, Bruce, M, Knighton, S, Scalori, A, Gera, A, Hughes, S, Al-Freah, M, Suddle, A, Agarwal, K, Harrison, P.M

Volltext

OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC) von Horinouchi, H., Solomon, B.J., Wu, Y.-L., Barlesi, F., Nishio, M., Ahn, J.S., Lee, D.H., Lee, J.-S., Zhong, W., Hochmair, M., Bondarenko, I., Planchard, D., Rittmeyer, A., Ding, B., Ruf, T., Adler, L., Scalori, A., Dziadziuszko, R.

Volltext

LBA1 Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK+ non-small cell lung cancer (NSCLC): A... von Ahn, J.S., Wu, Y-L., Dziadziuszko, R., Barlesi, F., Nishio, M., Lee, D.H., Lee, J-S., Zhong, W-Z., Horinouchi, H., Mao, W., Lu, S., Wang, Q., Yang, C-T., Korphaisarn, K., Xu, T., Bu, L., Scalori, A., Petric, P., Redhead, K., Solomon, B.

Volltext

650 HEPATITIS B VIRUS DNA LEVELS AND ALT PREDICT SEVERITY OF LIVER INJURY IN CHRONIC HBEAG NEGATIVE DISEASE von Carey, I, Taylor, N, Hughes, S, Scalori, A, Bruce, M, Horner, M, Oakes, K, Hodgson, S, Harrison, P

Volltext

1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC) von Hu, M.I., Subbiah, V., Mansfield, A.S., Taylor, M., Schuler, M.H.H., Zhu, V., Hadoux, J., Curigliano, G., Wirth, L.J., Garralda, E., Adkins, D.R., Godbert, Y., Ahn, M-J., Cassier, P.A., Cho, B.C., Lin, C-C., Barata, T., Zalutskaya, A., Scalori, A., Brose, M.S.

Volltext

Risk factors for focal nodular hyperplasia of the liver: an Italian case-control study von Scalori, Astrid, Tavani, Alessandra, Gallus, Silvano, La Vecchia, Carlo, Colombo, Massimo

Volltext

Interferon-induced depression: prevalence and management von Scalori, A., Pozzi, M., Bellia, V., Apale, P., Santamaria, G., Bordoni, T., Redaelli, A., Avolio, A., Parravicini, P., Pioltelli, P., Roffi, L.

Volltext

P224 Responder definitions for the ulcerative colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) tool using patients with ulcerative colitis treated with etrolizumab von Higgins, P, Matsui, A, DeBusk, K, Pulley, J, Scalori, A, Oh, Y S, Arulmani, U

Volltext

Psychological screening before interferon therapy von Scalori, Astrid, Apale, Paolo, Roffi, Luigi

Volltext

P136 Association between histological indices and ulcerative colitis activity measures among patients in the HICKORY (etrolizumab) open-label induction cohort von Peyrin-Biroulet, L, Feagan, B, Pai, R K, Arulmani, U, Boruvka, A, Oh, Y S, Scherl, A, Scalori, A, Arrisi, P, Tole, S, Rubin, D T

Volltext

P23 Target And Biomarker Discovery For Hedgehog Pathway Activity In Idiopathic Pulmonary Fibrosis In Support Of A Phase 2 Randomised, Double-blind, Placebo-controlled Study To Asse... von Jia, G., Chandriani, S., Abbas, A., DePianto, D., N'Diaye, E., Yaylaoglu, M., Collard, H., Wolters, P., Egen, J., Scalori, A., Ackrill, A., Hou, J., Kaminski, J., Maher, T., Arron, J.

Volltext

Course of focal nodular hyperplasia (FNH) in 24 asymptomatic carriers von De Fazio, C, Fasani, P, Donato, M F, Ronchi, G, Scalori, A, Pacchetti, S, Colombo, M

Volltext

Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy von Colloredo, G., Roffi, L., Brunetto, M. R., Leandro, G., Brugnetti, B., Bissoli, F., Scalori, A., Mancia, G., Civardi, E., Idéo, G., Bonino, F., Bellati, G.

Volltext